Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company ...

LONDON, GREATER LONDON, UNITED KINGDOM, March 4, 2025 /EINPresswire / -- How Has the Beyfortus Market Expanded in Recent Years? The Beyfortus market has experienced significant growth, driven by ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

The incident occurred months after health authorities discovered the GP’s clinic had incorrectly stored vaccines, potentially ...

Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12 ...

Dupixent made about €13 billion in its first full year, while Beyfortus, a novel RSV vaccination for babies, became a bestseller with €1.7 billion. SNY’s EPS grew 4.1% at CER to €7.12 ...

Beyfortus (nirservimab) offered strong protection against respiratory syncytial virus (RSV)-related outcomes in infants and young children, according to a recent study published in JAMA Network. RSV ...

“Nirsevimab, very exciting, also known as Beyfortus, is a monoclonal antibody. It is recommended for infants under the age of 8 months entering their first RSV season,” Capusan explained. While supply ...